// App-Quantinova.ai

: Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

Researchers

Presenter

  • Rahul Palchaudhuri

Principal Investigators

  • Jennifer L Proctor

  • Sharon L. Hyzy

  • Sharon Aslanian

  • Sean M McDonough

  • Ganapathy Sarma

  • Melissa L. Brooks

  • Anjali Bhat

  • Danielle Ladwig

  • Molly A McShea

  • Nathan M Kallen

  • Qing Li

  • Rajiv Panwar

  • Junia Dushime

  • Pranoti Sawant

  • Hillary L Adams

  • Patrick C. Falahee

  • Tahirih L Lamothe

  • Andrew D Gabros

  • Lena Kien

  • Geoff Gillard

  • Charlotte F McDonagh

  • Anthony E. Boitano

  • Michael P. Cooke

Medical Centers

  • Jounce Therapeutics, Cambridge, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Obstetrics/Gynecology

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Infertility

Biomarkers

  • Nucleophosmin 1

  • Cluster of Differentiation 34

  • Fms related tyrosine kinase 3

  • Immunoglobulin G

  • Apparent diffusion coefficient

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved